Hematology

FDA grants Priority Review to Agios’ mitapivat sNDA for sickle cell disease, with a PDUFA date set for November 1, 2026.

Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Catch up on the hematology news and data you missed from April 2026.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Catch up on the hematology headlines you missed in March 2026.

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

ASH publishes 33 clinical recommendations and 4 good practice statements for the diagnosis and treatment of severe and very severe acquired aplastic anemia.

Rapid NGS and streamlined workflows are critical to delivering timely, actionable genomic insights in blood cancers, but access, reimbursement, and expertise gaps persist.

In the first study of its kind, researchers found that physicians treating sickle cell disease experience burnout at a rate of 60% — driven not by personal factors, but by systemic ones.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.

The FDA granted Priority Review and accepted a New Drug Application for rusfertide to treat adults with polycythemia vera.

Panelist member explains new ASH guidelines aim to improve early diagnosis of AL amyloidosis with blood, urine, and biopsy testing.

Luspatercept met primary endpoints in transfusion-dependent and non–transfusion-dependent alpha-thalassemia.

In pediatric platelet transfusions, what counts as success depends on the clinical context and treatment goals, not just the platelet count.

The American Society of Hematology released new 2026 Guidelines for Management of Relapsed/Refractory ALL in AYAs, discussing immunotherapy and personalized decision making.

January 2026 Hematology Month in Review highlights new ASH and KDIGO guidelines, FDA approvals, and pipeline progress in rare blood disorders.

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

Robert Negrin discusses ASH initiatives to sustain hematology research, early-career careers, and global clinical programs.

ASH’s multidisciplinary panel provides a standardized diagnostic pathway emphasizing early laboratory testing and surrogate biopsies.